Cytokinetics (CYTK) Return on Equity (2016 - 2025)
Historic Return on Equity for Cytokinetics (CYTK) over the last 13 years, with Q3 2024 value amounting to 11.85%.
- Cytokinetics' Return on Equity fell 132000.0% to 11.85% in Q3 2024 from the same period last year, while for Sep 2024 it was 11.85%, marking a year-over-year decrease of 132000.0%. This contributed to the annual value of 2.12% for FY2023, which is 71800.0% up from last year.
- According to the latest figures from Q3 2024, Cytokinetics' Return on Equity is 11.85%, which was down 132000.0% from 3.76% recorded in Q2 2024.
- Over the past 5 years, Cytokinetics' Return on Equity peaked at 5.55% during Q4 2022, and registered a low of 11.85% during Q3 2024.
- In the last 5 years, Cytokinetics' Return on Equity had a median value of 0.82% in 2021 and averaged 0.37%.
- Examining YoY changes over the last 5 years, Cytokinetics' Return on Equity showed a top increase of 102700bps in 2020 and a maximum decrease of -1229400bps in 2020.
- Quarter analysis of 5 years shows Cytokinetics' Return on Equity stood at 0.84% in 2020, then rose by 2bps to 0.82% in 2021, then surged by 774bps to 5.55% in 2022, then plummeted by -77bps to 1.27% in 2023, then plummeted by -1032bps to 11.85% in 2024.
- Its Return on Equity was 11.85% in Q3 2024, compared to 3.76% in Q2 2024 and 1.35% in Q1 2024.